Vivek K.  Jayaraman net worth and biography

Vivek Jayaraman Biography and Net Worth

COO of Cerus
Mr. Jayaraman was appointed as Cerus’ Chief Operating Officer in March, 2020. In his role, Mr. Jayaraman oversees commercial operations, supply chain, customer service, and manufacturing operations. Previously, Mr. Jayaraman served as Cerus’ chief commercial officer from August 2016 and under his commercial leadership, Cerus’ global revenue more than doubled. Prior to joining Cerus in 2016, Mr. Jayaraman led TriVascular’s commercial expansion as the company grew from a preclinical, venture-backed startup into a publicly traded, global medical device company. At the time of its merger with Endologix, Inc. (NASDAQ: ELGX) in February 2016, TriVascular’s products were sold in over 30 countries. Prior to TriVascular, Mr. Jayaraman served in roles of increasing responsibility at Medtronic, Inc.; most recently serving as vice president of global marketing for Medtronic’s endovascular innovations business. Mr. Jayaraman received his MBA from the Wharton School at the University of Pennsylvania and holds dual bachelor’s degrees from the University of Michigan.

What is Vivek K. Jayaraman's net worth?

The estimated net worth of Vivek K. Jayaraman is at least $1.56 million as of March 13th, 2024. Mr. Jayaraman owns 905,447 shares of Cerus stock worth more than $1,557,369 as of November 15th. This net worth evaluation does not reflect any other investments that Mr. Jayaraman may own. Additionally, Mr. Jayaraman receives an annual salary of $696,680.00 as COO at Cerus. Learn More about Vivek K. Jayaraman's net worth.

How old is Vivek K. Jayaraman?

Mr. Jayaraman is currently 49 years old. There are 5 older executives and no younger executives at Cerus. The oldest executive at Cerus is Dr. Laurence M. Corash M.D., Co-Founder & Chief Scientific Officer, who is 80 years old. Learn More on Vivek K. Jayaraman's age.

What is Vivek K. Jayaraman's salary?

As the COO of Cerus Co., Mr. Jayaraman earns $696,680.00 per year. There are 2 executives that earn more than Mr. Jayaraman. The highest earning executive at Cerus is Mr. William M. Greenman, President, CEO & Director, who commands a salary of $1,040,000.00 per year. Learn More on Vivek K. Jayaraman's salary.

How do I contact Vivek K. Jayaraman?

The corporate mailing address for Mr. Jayaraman and other Cerus executives is 1220 CONCORD AVENUE SUITE 600, CONCORD CA, 94520. Cerus can also be reached via phone at (925) 288-6000 and via email at [email protected]. Learn More on Vivek K. Jayaraman's contact information.

Has Vivek K. Jayaraman been buying or selling shares of Cerus?

Vivek K. Jayaraman has not been actively trading shares of Cerus during the last quarter. Learn More on Vivek K. Jayaraman's trading history.

Who are Cerus' active insiders?

Cerus' insider roster includes Laurence Corash (Insider), Kevin Green (CFO), William Greenman (CEO), Vivek Jayaraman (COO), Chrystal Menard (Insider), Carol Moore (SVP), Gail Schulze (Director), and Daniel Swisher, Jr. (Director). Learn More on Cerus' active insiders.

Are insiders buying or selling shares of Cerus?

In the last year, Cerus insiders bought shares 3 times. They purchased a total of 15,000 shares worth more than $25,875.00. In the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 227,506 shares worth more than $488,803.79. The most recent insider tranaction occured on September, 3rd when CFO Kevin Dennis Green sold 28,385 shares worth more than $61,879.30. Insiders at Cerus own 3.4% of the company. Learn More about insider trades at Cerus.

Information on this page was last updated on 9/3/2024.

Vivek K. Jayaraman Insider Trading History at Cerus

See Full Table

Vivek K. Jayaraman Buying and Selling Activity at Cerus

This chart shows Vivek K. Jayaraman's buying and selling at Cerus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cerus Company Overview

Cerus logo
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Read More

Today's Range

Now: $1.72
Low: $1.69
High: $1.82

50 Day Range

MA: $1.79
Low: $1.52
High: $2.07

2 Week Range

Now: $1.72
Low: $1.38
High: $2.59

Volume

1,494,732 shs

Average Volume

1,298,101 shs

Market Capitalization

$319.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2